New PhRMA CEO: Drug Costs Must Be Viewed In Context
This article was originally published in Scrip
Executive Summary
With the biopharmaceutical industry frequently coming under attack over the past year about the high prices of certain medicines – decades-old drugs with significantly hiked up prices and expensive new innovative medications for hepatitis C virus (HCV) and severely uncontrolled cholesterol – the new head of the Pharmaceutical Research and Manufacturers of America (PhRMA) urged policymakers and patients to consider the costs of those products in context.